Methods of providing therapeutic effects using cyclosporin components
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/13
A61K-047/02
A61K-009/00
A61K-047/44
A61K-009/107
A61K-047/10
A61K-047/22
A61K-047/32
출원번호
US-0222478
(2014-03-21)
등록번호
US-9248191
(2016-02-02)
발명자
/ 주소
Acheampong, Andrew
Tang-Liu, Diane D.
Chang, James N.
Power, David F.
출원인 / 주소
Allergan, Inc.
대리인 / 주소
Wine, Laura L.
인용정보
피인용 횟수 :
0인용 특허 :
109
초록▼
Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The
Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
대표청구항▼
1. A method of treating dry eye disease, the method comprising topically administering to a human eye in need thereof a first topical ophthalmic emulsion at a frequency of twice a day, wherein the first topical ophthalmic emulsion comprises cyclosporin A in an amount of about 005% by weight, polysor
1. A method of treating dry eye disease, the method comprising topically administering to a human eye in need thereof a first topical ophthalmic emulsion at a frequency of twice a day, wherein the first topical ophthalmic emulsion comprises cyclosporin A in an amount of about 005% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer, water, and castor oil in an amount of about 1.25% by weight; wherein the method is therapeutically effective in treating dry eye disease;wherein the method provides overall efficacy substantially equal to administration of a second topical ophthalmic emulsion to a human eye in need thereof at a frequency of twice a day, the second emulsion comprising cyclosporin A in an amount of about 0.1% by weight and castor oil in an amount of about 1.25% by weight; andwherein the method results in substantially no detectable concentration of cyclosporin A in the blood of the human. 2. The method of claim 1, wherein the first topical ophthalmic emulsion further comprises a tonicity agent or a demulcent component. 3. The method of claim 2, wherein the tonicity agent or the demulcent component is glycerine. 4. The method of claim 1, wherein the first topical ophthalmic emulsion further comprises a buffer. 5. The method of claim 4, wherein the buffer is sodium hydroxide. 6. The method of claim 1, wherein the first topical ophthalmic emulsion further comprises glycerine and a buffer. 7. The method of claim 1, wherein the first topical ophthalmic emulsion comprises polysorbate 80 in an amount of about 1.0% by weight. 8. The method of claim 1, wherein the first topical ophthalmic emulsion comprises acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight. 9. The method of claim 1, wherein the first topical ophthalmic emulsion further comprises glycerine in an amount of about 2.2% by weight and a buffer. 10. The method of claim 9, wherein the buffer is sodium hydroxide. 11. The method of claim 2, wherein the first topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6. 12. The method of claim 1, wherein substantially no detectable concentration of cyclosporin A in the blood of the human means that the concentration of cyclosporin A in the blood of the human is less than about 0.1 ng/ml. 13. A method of enhancing tearing in a human eye, the method comprising topically administering to a human eye in need thereof a first topical ophthalmic emulsion at a frequency of twice a day, wherein the first topical ophthalmic emulsion comprises cyclosporin A in an amount of about 0.05% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer, water, and castor oil in an amount of about 1.25% by weight; wherein the method is therapeutically effective in treating dry eye disease and wherein the method achieves at least as much therapeutic efficacy as administration of a second topical ophthalmic emulsion to a human eye in need thereof at a frequency of twice a day, the second emulsion comprising cyclosporin A in an amount of about 0.1% by weight and castor oil in an amount of about 1.25% by weight; andwherein the method results in a concentration of cyclosporin A in the blood of the human of less than about 0.1 ng/ml. 14. The method of claim 13, wherein the first topical ophthalmic emulsion comprises acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight, polysorbate 80 in an amount of about 1.0% by weight, and wherein the first topical ophthalmic emulsion further comprises glycerine in an amount of about 2.2% by weight and a buffer. 15. The method of claim 14, wherein the first topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6. 16. The method of claim 13, wherein the method is effective in enhancing lacrimal gland tearing. 17. A method of treating dry eye disease, the method comprising topically administering to a human eye in need thereof a first topical ophthalmic emulsion at a frequency of twice a day, wherein the first topical ophthalmic emulsion comprises cyclosporin A in an amount of about 0.05% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer, water, and castor oil in an amount of about 1.25% by weight; and wherein the first topical ophthalmic emulsion breaks down more quickly in the human eye, once administered to the human eye, thereby reducing vision distortion in the human eye as compared to a second topical ophthalmic emulsion that contains only about 50% as much castor oil as the first topical ophthalmic emulsion. 18. The method of claim 17, wherein the first topical ophthalmic emulsion comprises acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight, polysorbate 80 in an amount of about 1.0% by weight, and wherein the first topical ophthalmic emulsion further comprises glycerine in an amount of about 2.2% by weight and a buffer. 19. The method of claim 18, wherein the first topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6. 20. The method of claim 19, wherein the method results in a concentration of cyclosporin A in the blood of the human of less than about 0.1 ng/ml. 21. A method of restoring tearing, the method comprising topically administering to a human eye in need thereof a first topical ophthalmic emulsion at a frequency of twice a day, wherein the first topical ophthalmic emulsion comprises cyclosporin A in an amount of about 0.05% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer, water, and castor oil in an amount of about 1.25% by weight; wherein the method demonstrates a reduction in adverse events in the human, compared to administration of a second topical ophthalmic emulsion to a human eye in need thereof at a frequency of twice a day, the second topical ophthalmic emulsion comprising cyclosporin A in an amount of about 0.1% by weight and castor oil in an amount of about 1.25% by weight; andwherein the method achieves at least as much therapeutic efficacy as administration of the second topical ophthalmic emulsion to a human eye in need thereof at a frequency of twice a day. 22. The method of claim 21, wherein the method results in a concentration of cyclosporin A in the blood of the human of less than about 0.1 ng/ml. 23. The method of claim 21, wherein the adverse events are selected from the group consisting of visual distortion and eye irritation. 24. The method of claim 21, wherein the first topical ophthalmic emulsion comprises acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight, polysorbate 80 in an amount of about 1.0% by weight, and wherein the first topical ophthalmic emulsion further comprises glycerine in an amount of about 2.2% by weight and a buffer. 25. The method of claim 24, wherein the first topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6. 26. The method of claim 21, wherein the method is effective in restoring lacrimal gland tearing. 27. The method of claim 21, wherein the adverse events are selected from the group consisting of visual distortion and eye irritation and wherein the method results in a concentration of cyclosporin A in the blood of the human of less than about 0.1 ng/ml.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (109)
Yamamura Yoshitaka,JPX ; Yamashita Tatsuya,JPX ; Nakamura Shigeki,JPX ; Onogawa Toshiyuki,JPX ; Yamada Yoshihisa,JPX ; Tsujimae Kenji,JPX ; Ogawa Hidenorii,JPX ; Mori Toyoki,JPX ; Tominaga Michiaki,J, Agent for prophylaxis or treatment of cataract.
Chartrain Michel M. (Westfield NJ) Katz Lorraine G. (Springfield NJ) King Steven A. (Summit NJ), Bioconversion process for the synthesis of transhydroxy sulfone by Rhodotorula rubra or Rhodotorula pil.
Kim Hyun Soo,KRX ; Choi Jae Yoon,KRX ; Lee Hye Weon,KRX ; Park Young Keun,KRX ; Choi Sung Wook,KRX, Cyclosporin containing composition and process for the preparation thereof.
Kim Jung W. (Seoul KRX) Shin Hee J. (Kyeonggi-do KRX) Park Joon K. (Kyeonggi-do KRX) Min Kyeong B. (Seoul KRX), Cyclosporin containing powder composition.
Ding Shulin ; Olejnik Orest ; Reis Brenda L., Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers.
Al-Razzak Laman A. ; Constantinides Panayiotis Pericleous ; Kaul Dilip ; Lipari John M. ; McChesney-Harris Lisa L. ; Abdullah Bashar Y., Hydrophilic binary systems for the administration of lipophilic compounds.
Orbn Erno (Budapest HUX) Balogh Tibor (Budapest HUX) Ila Lajos (Budapest HUX) Ambrus Gbor (Budapest HUX) Jekkel Antnia (Budapest HUX) Elek Sndor (Budapest HUX) Tomori va (Budapest HUX) Elekes Istvn (, Intravenous pharmaceutical composition and process for preparing the same.
David B. Bennett ; Kirsten M. Cabot ; Linda C. Foster ; David Lechuga-Ballesteros ; John S. Patton ; Trixie K. Tan, Liquid crystal forms of cyclosporin.
Walch Hatto (Laupheim -Baustetten DEX) Fleck Monika (Laupheim DEX) Neuer Klaus (Grossschafhausen DEX), Liquid preparations containing cyclosporin and process for preparing same.
Caufield Craig E. (Plainsboro NJ) Musser John H. (Pacific Marina CA) Sehgal Surendra N. (Princeton NJ), Method of treating immunoinflammatory bowel disease.
Nussenblatt Robert B. (Bethesda MD) Palestine Alan G. (Potomac MD), Method of treating ocular diseases by periocular administration of cyclosporine A or G.
Hewitt Charles W. (698 Tranquility Turn Marlton NJ 08053) Black Kirby S. (13401 Sussex Pl. Santa Ana CA 92705), Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants.
Andrieu J. M. (7 Rue du Val de Grace 75007 Paris FRX) Even P. (59 Rue Vaneau 75007 Paris FRX) Venet Alain (5 MS Quoi de lo Rifubli 94410 Saint Maurice FRX), Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus.
Shahar Arie (2800-187 Plaza Del Amo Torrance CA 90503) Schwartz Nira (2800-187 Plaza Del Amo Torrance CA 90503) Woods Richard W. (2800-187 Plaza Del Amo Torrance CA 90503), Shielding device for improving measurement accuracy and speed in scanning electron microscopy.
MacGilp Neil A. (Cincinnati OH) Baier Kathleen G. (Cincinnati OH) Girardot Richard M. (Cincinnati OH) Torres Efrain (Cincinnati OH), Stable mild liquid soap personal cleanser.
Sallee Verney L. ; DeSantis ; Jr. Louis ; Zinke Paul W. ; Bishop John E., Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.